Fate Therapeutics, Inc. (FATE)
1.775
-0.16
(-8.51%)
USD |
NASDAQ |
Nov 10, 16:00
1.775
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Cash from Operations (Annual) : -106.08M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -106.08M |
| December 31, 2024 | -122.87M |
| December 31, 2023 | -132.26M |
| December 31, 2022 | -248.21M |
| December 31, 2021 | -162.87M |
| December 31, 2020 | -39.23M |
| December 31, 2019 | -83.18M |
| December 31, 2018 | -38.65M |
| Date | Value |
|---|---|
| December 31, 2017 | -36.90M |
| December 31, 2016 | -29.82M |
| December 31, 2015 | -18.40M |
| December 31, 2014 | -22.42M |
| December 31, 2013 | -15.37M |
| December 31, 2012 | -13.27M |
| December 31, 2011 | -12.14M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| AVITA Medical, Inc. | -31.20M |
| Agenus, Inc. | -77.20M |
| Amgen, Inc. | 9.958B |
| Anika Therapeutics, Inc. | 11.19M |
| BioCryst Pharmaceuticals, Inc. | 329.88M |